DERM Stock Risk & Deep Value Analysis
Journey Medical Corp
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About DERM Stock
We analyzed Journey Medical Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran DERM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
DERM Risk Analysis & Red Flags
What Could Go Wrong
The primary risk is a **non-approval of DFD-29 by the FDA in Q3 2026**. This single event, such as a Complete Response Letter (CRL), would severely impact DERM's future revenue potential, which is heavily reliant on DFD-29's success, and could lead to a stock price depreciation of 70-80% from its current $6.18 level.
Risk Matrix
Overall
Aggressive
Financial
Medium-High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
High dependency on a single pipeline asset (DFD-29) for significant future growth, making the stock highly binary.
- ⚠
Consistent net losses, despite narrowing (Q1 2026 GAAP net loss of $2.23M), indicates ongoing cash burn prior to DFD-29 commercialization.
- ⚠
Lack of specific analyst consensus or institutional sentiment data in the provided research, suggesting limited coverage for a company facing a critical regulatory decision.
Upcoming Risk Events
- 📅
DFD-29 Complete Response Letter (CRL) from FDA (Q3 2026): Non-approval would eliminate a significant portion of future revenue potential and trigger a substantial stock price decline.
- 📅
Q2 2026 Earnings Miss (estimated August 11, 2026): Failure to maintain 20%+ YoY revenue growth or a return to significant operating losses could raise concerns about commercial execution for existing products and cash burn.
When to Reconsider
- 🚪
DFD-29 receives a Complete Response Letter (CRL) from the FDA or is otherwise not approved.
- 🚪
Quarterly revenue for existing products drops below $15M or shows negative YoY growth for two consecutive quarters.
- 🚪
Cash and cash equivalents fall below $15M, signaling potential immediate funding needs or significantly shortened runway without successful DFD-29 approval.
Unlock DERM Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Journey Medical Corp (DERM) Do?
Market Cap
$165.21M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
41
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Visit Journey Medical Corp WebsiteInvestment Thesis
If DFD-29 for rosacea receives FDA approval in Q3 2026 and subsequently achieves significant market penetration, reaching peak annual sales of $200-$300 million within 3-5 years, then DERM could see its valuation expand to over $1 billion, translating to a 5-10x return. This is bullish because the current $0.17B market cap largely underappreciates DFD-29's full commercial potential and differentiated profile post-approval.
Is DERM Stock Undervalued?
Unlock the full AI analysis for DERM
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
DERM Price Targets & Strategy
12-Month Target
$20.00
Bull Case
$60.00
Bear Case
$2.00
Valuation Basis
12-month target: 3.0x estimated 2027 revenue of $200M (post-DFD-29 approval & initial ramp) = $600M market cap.
Entry Strategy
Dollar-cost average below $6.00, accumulating shares prior to the DFD-29 PDUFA decision expected in Q3 2026. Consider entry on dips towards recent support levels if DFD-29 approval is highly anticipated.
Exit Strategy
Take initial profit at $20.00 (post-PDUFA approval). Consider scaling out 50% at $30.00, and remaining position at $50.00+ if DFD-29 commercialization excels. Implement a stop-loss at $3.00 if DFD-29 receives a Complete Response Letter (CRL).
Portfolio Allocation
5% for aggressive risk tolerance, given the binary nature of the primary catalyst.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is DERM Financially Healthy?
Valuation
P/E Ratio
3.40
Forward P/E
7.20
EV/EBITDA
7.90
PEG Ratio
0.28
Price/Book
1.70
Price/Sales
1.60
Profitability
Gross Margin
65.44%
Operating Margin
-9.80%
Net Margin
-14.82%
Return on Equity
-35.57%
Revenue Growth
15.00%
EPS
$-0.38
Balance Sheet
Current Ratio
1.79
Quick Ratio
1.44
Debt/Equity
0.79
Total Debt
$41.00M
Cash & Equivalents
$21.00M
Cash Flow
Operating Cash Flow
$28.00M
Free Cash Flow
$19.00M
EBITDA
$38.00M
Other
Beta (Volatility)
1.09
Does DERM Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Expanding
Moat Sources
1 Identified
The moat is currently limited but could expand significantly with the successful FDA approval and commercialization of DFD-29, which would be protected by patents. Its durability depends on the strength of DFD-29's IP and its clinical differentiation against existing and future treatments.
Moat Erosion Risks
- •Failure of DFD-29 to secure FDA approval or achieve significant market penetration.
- •Introduction of new, superior, or more cost-effective therapies by larger pharmaceutical competitors in the dermatology space.
DERM Competitive Moat Analysis
Sign up to see competitive advantages
DERM Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - No specific data available in the provided research to indicate strong retail investor sentiment.
Institutional Sentiment
Neutral - The provided search results do not include a verified buy/hold/sell breakdown, median target, high/low target, or latest analyst rating change.
Insider Activity (Form 4)
No specific Form 4 filings, insider buy/sell details, or dollar values were provided in the search results.
Options Flow
Normal options activity - No specific unusual options activity or put/call ratio data was provided in the search results.
Earnings Intelligence
Next Earnings
Estimated August 11, 2026
Surprise Probability
Medium
Historical Earnings Pattern
No specific historical pattern is available from the provided data; however, similar biopharma companies with binary catalysts are highly sensitive to regulatory news and pipeline updates.
Key Metrics to Watch
Competitive Position
Top Competitor
Not available in the provided research context.
Market Share Trend
Not available in the provided research context.
Valuation vs Peers
Not available in the provided research context.
Competitive Advantages
- •Potential for a differentiated therapeutic profile for DFD-29 in the rosacea market.
- •Established commercial infrastructure and expertise in dermatology products through its existing portfolio.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive DERM Stock Higher?
Near-Term (0-6 months)
- •DFD-29 PDUFA decision (Q3 2026): FDA approval could trigger a 2x-3x re-rating in market cap to ~$400-$500M.
- •Q2 2026 Earnings Report (estimated August 11, 2026): Continued 20%+ YoY revenue growth for existing portfolio and positive Adjusted EBITDA could signal strong operational execution.
Medium-Term (6-18 months)
- •DFD-29 Initial Commercialization & Sales Ramp (Q4 2026 - Q2 2027): Successful launch and early physician adoption leading to DFD-29 revenue exceeding $15M/quarter.
- •Strategic Partnerships/Licensing Deals (H1 2027): Potential for ex-US licensing agreements for DFD-29, providing non-dilutive capital and expanded market reach.
Long-Term (18+ months)
- •DFD-29 Peak Sales Achievement (FY2028-2029): DFD-29 capturing 10-15% of the rosacea market, driving total annual revenue to $200M-$300M, supporting a potential $1B+ market cap.
- •Pipeline Expansion (FY2029+): In-licensing or developing additional differentiated dermatology assets that leverage existing commercial infrastructure, driving sustained revenue growth beyond DFD-29.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for DERM?
- ✓
FDA approval for DFD-29, indicating the primary catalyst has de-risked the pipeline.
- ✓
Emrosi® quarterly revenue consistently exceeding $7M, signaling continued strength in existing commercial products.
- ✓
Cash & Equivalents consistently above $25M, demonstrating a manageable cash burn and sufficient runway for DFD-29 launch.
Bull Case Analysis
Sign up free to see the bull case
Competing with DERM
See how Journey Medical Corp compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Journey Medical Corp DERM | $165.2M | 8.0 | 3.4 | $139.2M | -14.8% | 15.0% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Journey Medical Corp Makes Money
Journey Medical Corp (DERM) is a commercial-stage pharmaceutical company focused on acquiring, developing, and commercializing innovative dermatology products. It makes money by selling prescription medications for various skin conditions, primarily through its existing portfolio like Emrosi® for rosacea ($6.3M revenue in Q1 2026), and is heavily investing in its pipeline drug, DFD-29, which is awaiting FDA approval for rosacea and is expected to be a major revenue driver.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Journey Medical Corp (DERM)?
As of June 10, 2026, Journey Medical Corp has a DVR Score of 8.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Journey Medical Corp?
Journey Medical Corp's market capitalization is approximately $165.2M. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.
What ticker symbol does Journey Medical Corp use?
DERM is the ticker symbol for Journey Medical Corp. The company trades on the NCM.
What is the risk level for DERM stock?
Our analysis rates Journey Medical Corp's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of DERM?
Journey Medical Corp currently has a price-to-earnings (P/E) ratio of 3.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Journey Medical Corp's revenue growing?
Journey Medical Corp has reported revenue growth of 15.0%. The company is showing strong top-line momentum.
Is DERM stock profitable?
Journey Medical Corp has a profit margin of -14.8%. The company is currently unprofitable.
How often is the DERM DVR analysis updated?
Our AI-powered analysis of Journey Medical Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 10, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for DERM (Journey Medical Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.